-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: Biotechnology Industry Organization
FDA: How can we improve it?
By Stephen Sherwin, Former Chairman of BIO As Congress and the President work together to hammer out a new, national economic roadmap, it is important to point out to those working in, and interested in, our industry that we too have recently assembled a roadmap – one designed to fully realize the promise our industry holds for people everywhere. Several weeks ago, at the 2011 BIO International Convention in Washington, DC, BIO unveiled its first ever 5 Read More >
How we are advancing American innovation to cure disease and save lives
Mankind’s need to cure disease, combat hunger and discover new forms of energy has never been more urgent. Yet despite the extraordinary hope offered by biotechnology to solve these problems, government policies and the capital formation environment necessary to support these goals are insufficiently conducive to allowing us to meet these critical challenges. During our 2011 BIO International Convention, we unveiled a strategic initiative to speed scientific breakthroughs, develop cures and grow the bio-economy. The Read More >
BIO Hosts U.S./China Biotechnology Examiner Workshop with U.S. Patent and Trademark Office and China’s State Intellectual Property Office
Press Release: WASHINGTON, D.C. (Tuesday, April 05, 2011) – The Biotechnology Industry Organization (BIO) hosted a U.S./China Biotechnology Examiner Workshop with U.S. Patent and Trademark Office (PTO) and China’s State Intellectual Property Office (SIPO) on March 28, 2011 in Beijing, China. The workshop which was organized by BIO for SIPO examiners, focused on biotechnology patenting and encouraged bilateral cooperation between SIPO and the USPTO.“BIO recognizes the commitment on behalf of the Chinese Government and Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: Access and Benefit Sharing, Beijing, BIO, biotechnology, Biotechnology Industry Organization, China, Chinese Patent Office, claim homology, enablement, Events, Examiner workshop, genetic resources, patent, patent disclosure, patent law, PTO, sequence homology, SIPO, United States Patent and Trademark Office, USPTO, written description
Tags: Access and Benefit Sharing, Beijing, BIO, biotechnology, Biotechnology Industry Organization, China, Chinese Patent Office, claim homology, enablement, Events, Examiner workshop, genetic resources, patent, patent disclosure, patent law, PTO, sequence homology, SIPO, United States Patent and Trademark Office, USPTO, written description
BIO’s Amicus Brief: Microsoft v. i4i
The Biotechnology Industry Organization, along with AUTM and CropLife International, filed an amicus brief in the Microsoft v. i4i Supreme Court case. This case is widely viewed as one of the most fundamental and important patent cases to reach the Supreme Court in probably a decade. Most basically, this case is about the level of certainty a jury or judge must have before finding a patent invalid in litigation. Historically, the law has required a high level Read More >
Patently BIOtech
1 Comment
Email This Post
Tags: amicus brief, AUTM, BIO, biotechnology, Biotechnology Industry Organization, burden of proof, clear and convincing evidence, CropLife, i4i, Microsoft, Microsoft v. i4i, patent, Patent and Trademark Office, preponderance of the evidence, PTO, Supreme Court, USPTO
Tags: amicus brief, AUTM, BIO, biotechnology, Biotechnology Industry Organization, burden of proof, clear and convincing evidence, CropLife, i4i, Microsoft, Microsoft v. i4i, patent, Patent and Trademark Office, preponderance of the evidence, PTO, Supreme Court, USPTO
